Combination Therapy for Testicular Lymphoma Gives Reassuring Results

A high rate of progression-free survival was achieved with systemic immune chemotherapy, intrathecal prophylaxis, and radiation therapy to the contralateral testis.

Primary testicular diffuse large B-cell lymphoma (DLBCL) is rare and usually presents with stage IE or IIE disease but with a high propensity for relapse in the central nervous system (CNS) and other extranodal sites, including the contralateral testis. Now, researchers have conducted a multicenter phase II trial to investigate the effect of a combination treatment on progression-free survival (PFS) in patients with untreated stage I or II primary testicular DLBCL.

A total of 53 patients (median age, 62; range, 22–79) were enrolled and received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on a 21-day schedule for 6 to 8 cycles, CNS prophylaxis with intrathecal methotrexate for four doses, and radiation t…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee